Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb.


Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients.

Zuur MA, van Asselt ADI, van 't Boveneind-Vrubleuskaya N, Aleksa A, Postma MJ, Alffenaar JWC.

Int J Tuberc Lung Dis. 2018 Sep 1;22(9):991-999. doi: 10.5588/ijtld.17.0523.


Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.


Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May.


Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

van Rijn SP, Zuur MA, van Altena R, Akkerman OW, Proost JH, de Lange WC, Kerstjens HA, Touw DJ, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01783-16. doi: 10.1128/AAC.01783-16. Print 2017 Apr.


Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?

Zuur MA, Akkerman OW, Davies Forsman L, Hu Y, Zheng R, Bruchfeld J, Tiberi S, Migliori GB, Alffenaar JC.

Eur Respir J. 2016 Oct;48(4):1230-1233. doi: 10.1183/13993003.00833-2016. Epub 2016 Sep 1. No abstract available.


Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV.

Zuur MA, Akkerman OW, Touw DJ, van der Werf TS, Cobelens F, Burger DM, Grobusch MP, Alffenaar JW.

Eur Respir J. 2016 Sep;48(3):932-4. doi: 10.1183/13993003.00599-2016. Epub 2016 Jun 10. No abstract available.


Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.

Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W, van Soolingen D, Alffenaar JW.

Expert Opin Drug Metab Toxicol. 2016 May;12(5):509-21. doi: 10.1517/17425255.2016.1162785. Epub 2016 Mar 24. Review.


Supplemental Content

Support Center